XML 40 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Fair value measurements and investments (Tables)
9 Months Ended
Sep. 30, 2020
Fair Value Measurements And Investment Disclosure [Abstract]  
Schedule of Financial Assets and Liabilities Recorded at Fair Value on Recurring Basis

The fair value of the Company’s financial assets and liabilities measured on a recurring basis were as follows:

 

 

 

September 30,

2020

 

 

December 31,

2019

 

(U.S. Dollars, in thousands)

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

 

Total

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bone Biologics equity securities

 

$

 

 

$

 

 

$

 

 

$

 

 

$

219

 

Total

 

$

 

 

$

 

 

$

 

 

$

 

 

$

219

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Spinal Kinetics contingent consideration

 

$

 

 

$

 

 

$

(35,100

)

 

$

(35,100

)

 

$

(42,700

)

Other contingent consideration

 

$

 

 

$

 

 

$

(375

)

 

$

(375

)

 

$

 

Deferred compensation plan

 

 

 

 

 

(1,366

)

 

 

 

 

 

(1,366

)

 

 

(1,255

)

Total

 

$

 

 

$

(1,366

)

 

$

(35,475

)

 

$

(36,841

)

 

$

(43,955

)

 

Schedule of Reconciliation For Contingent Consideration Measured At Fair Value Using Significant Unobservable Inputs

The following table provides a reconciliation of the beginning and ending balances for the Spinal Kinetics contingent consideration measured at estimated fair value using significant unobservable inputs (Level 3):

 

(U.S. Dollars, in thousands)

 

2020

 

 

2019

 

Spinal Kinetics contingent consideration estimated fair value at January 1

 

$

42,700

 

 

$

28,560

 

Increase (decrease) in fair value recognized in acquisition-related amortization and remeasurement

 

 

(7,600

)

 

 

28,140

 

Payment made

 

 

 

 

 

(15,000

)

Spinal Kinetics contingent consideration estimated fair value at September 30

 

$

35,100

 

 

$

41,700

 

Schedule of Valuation Methodology and Unobservable Inputs for Level 3 Assets and Liabilities Measured at Fair Value

The following table provides a range of key assumptions used within the valuation as of September 30, 2020.

 

(U.S. Dollars, in thousands)

 

Fair Value as of

September 30, 2020

 

 

Valuation Technique

 

Unobservable inputs

 

Range

Spinal Kinetics contingent consideration

 

$

35,100

 

 

Discounted cash flow

 

Revenue discount rate

 

7.41% - 7.49%

 

 

 

 

 

 

 

 

Payment discount rate

 

4.33% - 4.40%

 

 

 

 

 

 

 

 

Projected year of payment

 

2021 - 2022

 

Schedule of Held to Maturity Debt Securities and Warrant Reconciliation

The following table provides a reconciliation of the beginning and ending balances for the eNeura debt security and warrant measured and reflected in the condensed consolidated balance sheets at fair value using significant unobservable inputs (Level 3) prior to the settlement discussed above:

 

(U.S. Dollars, in thousands)

 

2020

 

 

2019

 

eNeura debt security and Warrant at January 1

 

$

 

 

$

17,820

 

Gains or losses recorded for the period

 

 

 

 

 

 

 

 

Recognized in other comprehensive income (loss)

 

 

 

 

 

(2,593

)

Change in classification of debt security to held to maturity

 

 

 

 

 

(15,227

)

Issuance of Warrant as consideration for prior extension of debt maturity date

 

 

 

 

 

491

 

Impairment of warrant

 

 

 

 

 

(491

)

eNeura debt security and Warrant at September 30

 

$

 

 

$